Health Care/Hospital

Sedana Medical submits market approval application for the drug Sedaconda

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care. The applica...

2020-11-27 20:35 2906

Covid-19 Survivor: Showing Different Symptoms, Food Intake is Important in the Recovery Process

* Discipline in adhering to health protocols is a shared responsibility JAKARTA, Indonesia, Nov. 27, 2020 /PRNewswire/ -- All parties must adhere to health protocols as best they can in order to keep the Covid-19 transmission low. In addition, everyone must always maintain a strong immune syste...

2020-11-27 15:59 2084

Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time

HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, on...

2020-11-27 14:30 6140

Kingston Partners with CSD in APAC to Unleash the Power of Memories

TAIPEI, Nov. 27, 2020 /PRNewswire/ -- Moving forward its vision of preserving memories, Kingston Technology, a world leader of memory products and technology solutions, announced a creative alliance with CSD, a leading brand of face masks, to kickstart a one of a kind initiative, Kingston x CSD A...

2020-11-27 14:16 3052

Nanoform launches technology for biologics and sets new near-term business target for 2021

HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its ...

2020-11-27 14:04 1967

NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium

TAIPEI, Nov. 27, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the Covid-19 epidemic. During the 5-day conference, participants presented and exchanged in...

2020-11-27 12:21 1756

Amorepacific Develops an Original Technology That Reverses the Aging of Skin Cells in Joint Research with KAIST

SEOUL, South Korea, Nov. 27, 2020 /PRNewswire/ -- Amorepacific R&D Center, together with KAIST, developed an original technology that reverses the aging process in human dermal fibroblasts. The system's biology research was conducted in collaboration with a research team led by ProfessorCho Kwang...

2020-11-27 09:00 3622

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...

2020-11-27 08:42 2693

Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis

LONDON, Nov. 27, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.  The first-in-human trial initiated last year in heal...

2020-11-27 08:39 2497

Nose Filler Injection Can Cause Vision Loss When Injected With Poor Injection Techniques & Without Understanding Of Facial Anatomy, Dr Ivan Puah Warns

SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Dermal fillers using hyaluronic acid is one of the common types of soft-tissue augmentation used inSingapore for nose enhancement. Medical Director of Amaris B. Clinic, DrIvan Puah warns that when inexperienced medical injectors or non-medical professio...

2020-11-26 22:07 2768

China.org.cn: Seminar calls for global poverty reduction innovation, cooperation amidst pandemic

BEIJING, Nov. 26, 2020 /PRNewswire/ -- The 2020 International Seminar on Global Poverty Reduction Partnerships was held in Longnan city,Gansu province, China, onNov. 24. More than 100 participants from governments, academia, international organizations, NGOs, and the private sector attended the s...

2020-11-26 22:00 2021

Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia

TAIPEI, Nov. 26, 2020 /PRNewswire/ -- Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in ...

2020-11-26 21:35 2495

Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness

* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...

2020-11-26 16:44 6215

Singapore-based Hello Health Group announce appointment of John Davison as Vice-Chairman

SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Hello Health Group, a leading Digital Health company inAsia focusing on the development of health and wellness information platforms and services in local languages for consumers and patients, is excited to announce the appointment ofJohn Davison as Vice-...

2020-11-26 16:40 3073

Deep Longevity Adds Partnership with My Care Express in Merrillville To Add Biomarkers of Aging and Longevity

HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK)'s Deep Longevity, Inc, a company subject to a conditional acquisition by the Group which is a pioneer in deep biomarkers of aging...

2020-11-26 16:00 11403

Interim report, May-October 2020/21

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...

2020-11-26 15:01 6731

Gustaf Salford appointed Elekta CEO by Board of Directors

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Gustaf Salford has been appointed to the role of President and CEO, effective immediately. He has been Acting CEO since earlyJune 2020. Elekta's Board of Directors carried out an extensive search process, with the c...

2020-11-26 14:59 5919

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 14:04 5868

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational New D...

2020-11-26 10:34 1974

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 10:32 5439
1 ... 711712713714715716717 ... 858